Review of Evidence for the Usage of Antioxidants for Eye Aging

Abstract

Oxidative stress is one of the common factors leading to age-related eye diseases in older adults. Factors such as high oxygen consumption, high concentration of polyunsaturated fatty acids, and cumulative exposure to high-energy visible light in the eyes, lead to excessive generation of reactive oxygen species, hence triggering apoptosis of ocular cells and giving rise to ophthalmic diseases. Dietary supplements such as carotenoids, anthocyanins, and vitamins have antioxidant properties which may be of benefit in retaining better vision or reversing vision impairment; thus, studies have been conducted to understand the role of dietary supplements in the treatment or prevention of ophthalmic diseases. While high concentration of carotenoids such as lutein and zeaxanthin decrease the risk of developing age-related macular disease, anthocyanins and vitamins play a role in the treatment and prevention of other ophthalmic diseases: saffron extract reduced intraocular pressure in glaucoma patients; bilberry extract prevented impairments in lenses and retina, as well as alleviate symptoms of dry eye disease; high concentration of beta-carotene may reduce the risk of developing cataract. Further studies with clinical measurements are required to investigate the effectiveness of antioxidants on visual function and ophthalmic diseases.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Main Text

Proper eye healthcare is a vital component of maintaining one’s overall health. Negligent care of the eyes contributes to a multitude of ophthalmic diseases, resulting in impaired vision and affecting daily activities. These diseases may be minor in themselves, resulting in relatively insignificant symptoms such as slight inflammation or irritation. However, over time, more serious diseases may result in significant eye damage, decreased quality of vision, or total blindness.

Approximately 250 million people worldwide suffer from varying degrees of vision loss [1]. The leading causes of vision loss are common eye conditions such as cataracts, age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR), which largely affect older adults. While the origins and causes of age-related eye diseases are complex and multifactorial, oxidative stress has been implicated as a common conducive mechanism. The eye is susceptible to oxidative stress due to its high oxygen consumption, high concentrations of polyunsaturated fatty acids, and cumulative exposure to high-energy visible light. These factors combined lead to excessive generation of reactive oxygen species (ROS), which are free radicals containing oxygen, and can trigger oxidative damage to deoxyribonucleic acid (DNA), proteins, and lipids [2], inducing apoptosis of ocular cells and resulting in ophthalmic diseases [3]. It has been hypothesized that antioxidants may be of benefit in retaining better vision or even reversing vision impairment. Therefore, there is significant research interest in the role of dietary antioxidants and the potential therapeutic benefits of antioxidant supplements as a simple and cost-effect strategy for disease prevention and/or control [4–7]. This review will focus on the antioxidant properties of carotenoids (lutein and zeaxanthin), anthocyanins (saffron and bilberry), and vitamins (vitamin A) in the context of treating or preventing age-related eye diseases.

1.1. Evidence for Carotenoids

Xanthophyll (oxygen-containing) carotenoids, including lutein and zeaxanthin, are selectively concentrated in vision-related tissues (the eye and brain) [8]. Nearly all human ocular structures except the vitreous, cornea, and sclera contain lutein, zeaxanthin, and metabolites. The macula contains lutein and zeaxanthin with concentrations up to 100-fold higher than elsewhere in the eye [9]. Macular carotenoids are estimated to absorb 40 to 90% of incident blue light (depending on concentration) [10], protecting the retina from light-related damage [11] and reducing light scatter. The presence of oxidized metabolites in the retinal pigment epithelium (RPE), lens, ciliary body, and iris also suggests that lutein and zeaxanthin are protective against oxidative stress [12]. Lutein and zeaxanthin have also been found to prevent the increase in oxidation-induced cytokines and upregulate the expression of inflammation-related genes [13, 14]. In addition to its retinal effects, intake of a lutein supplement has been found to lower circulating levels of a rate-limiting enzyme in the alternative complement activation pathway, which itself plays an important role in the inflammatory response and the development of AMD [15, 16].

Several studies have demonstrated evidence of an inverse relationship between the presence of lutein and zeaxanthin in the retina and the risk for AMD [17–21]. An increase in macular pigment optical density (MPOD) level, where approximately 16.8 to 27.9% change in MPOD ($P<0.001$), and a small nonsignificant improvement in visual acuity (VA) have been found in AMD patients who received oral lutein supplements for six months [22] and over one year [23]. An electroretinographic study has shown that the use of carotenoid supplements containing lutein, zeaxanthin, and meso-zeaxanthin may improve the visual function of type 2 diabetes patients [24], where best-corrected visual acuity (BCVA) remained normal (≥9/10) in each eye, while mean central foveal thickness (CFT) increased approximately 5 to 7 μm in each eye ($P<0.001$). Multifocal electroretinography (mfERG) has revealed a significantly increased retinal response density surrounding the fovea (all central 3 rings) in both eyes two years after carotenoids supplement intake in type 2 diabetes patients ($P<0.001$). Additionally, daily intake of lutein supplements in healthy individuals also showed increased MPOD levels alongside improvement in contrast and glare sensitivity [25]; with a significant increase in MPOD levels at the more central measured eccentricities after 6 months of intervention, significant improvement in contrast sensitivity after 3 months of intervention, and change in glare sensitivity threshold after a year of intervention.

Higher lutein and zeaxanthin levels in the diet or blood are associated with decreased risk of macular disease [26–35]. However, many factors affect the degeneration of macular pigments, including physical inactivity, poor diet, low levels of lutein and zeaxanthin in the diet and serum, smoking, components of metabolic syndrome (i.e., obesity, diabetes, and hypertension), and common variants in genes related to macular pigment optical density (MPOD) and/or serum lutein and zeaxanthin [36]. These factors help in predicting the odds of developing early/intermediate AMD [37].

A reduction in genetic risk for AMD among individuals with high lutein and zeaxanthin intake has been observed among several cohorts (the Rotterdam Study [38], a pooled analysis of the Rotterdam and Blue Mountain Eye studies [39], and Carotenoids in Age-related Eye Disease Study (CAREDS) [40]). Despite the lowest rates of AMD being reported in individuals consuming 5 to 6 mg/day [41–44], diets high in lutein and zeaxanthin are also high in other carotenoids which may contribute to lower risk [44]. Lutein and zeaxanthin supplements alone did not influence AMD progression or have significant changes in BVCA over three years [45], as a significant increase in macular pigment (MP) was observed despite having significant improvements in contrast sensitivity at 36 months of intervention. However, slowed AMD progression was seen when combined with other antioxidant supplements [46]. Average BCVA in patients receiving an oral preparation containing lutein, zeaxanthin, vitamin C, vitamin E, copper, and zinc was approximately 4.8 letters better than the placebo group after 36 months ($P<0.05$). While these patients showed insignificant improvement in contrast sensitivity, slower AMD progression along a morphologic severity scale was observed.

The results of primary analyses in the Age-Related Eye Disease Study 2 (AREDS2) [47] trial suggest that including 10 mg of lutein and 2 mg of zeaxanthin in high-dose antioxidant supplements does not lower the progression to advanced AMD, as the hazard ratio (HR) compared with placebo were 0.89 to 0.97 ($P>0.05$) in all intervention groups. However, secondary analyses [48] have indicated a modestly lower five-year risk of progression in participants who began the study with low levels of lutein and zeaxanthin in their diets, or when the antioxidant supplements did not contain beta-carotene, as the hazard ratio appear to be less than 1 during the exploratory analyses and in eyes with bilateral large drusen at baseline ($P<0.05$ for development of late AMD and neovascular AMD). While there is no recommended daily intake for lutein and zeaxanthin, the intake of lutein is recommended to be higher than zeaxanthin among all age groups [49]. The health benefits of a daily intake of 10 mg of lutein and 2 mg of zeaxanthin have been shown in a randomized, double-blind, placebo-controlled human study [28].

Exposure to light at the retinal level increases phagocytosis in the outer segment (OS) of photoreceptors and induces the formation of ROS by RPE cells [50], followed by photooxidative stress in the retina when an imbalance develops between ROS and endogenous antioxidative systems [51]. Moreover, the impaired retinal antioxidant status may lead to the overexpression of proinflammatory and angiogenic mechanisms, which accounts for injured retinal microvasculature [52]. Nutritional supplements such as polyphenol and xanthophyll that scavenge ROS have been shown to prevent or delay the progression of early AMD by direct interaction with rhodopsin, modulate visual pigment function, and protect retinal cells from oxidative stress-induced cell death [53, 54]. Anthocyanins have been found to act directly as antioxidants to neutralize ROS by donating hydrogen ions and modulating cell signaling pathways [55], as well as effects on anti-inflammatory and antiapoptotic pathways and gene expression [56].

1.2. Evidence for Saffron

Crocus sativus L. (Iridaceae), commonly known as saffron, has been studied for its main components (crocins, crocetin, picrocrocin, and safranal) and its potent antioxidant activity [57–60], as well as the binding capacity of saffron metabolites to biomolecules, which protects them from free radicals [57, 61]. Saffron components have also been found to possess anti-inflammatory and antiapoptotic effects, possibly by the inhibition of caspase-mediated apoptosis after retinal damage [62–65], as well as to increase oxygen diffusion and improve retinal and choroidal blood flow [66, 67]. Studies on saffron extract suggest that it may exert a protective effect in patients with glaucoma. Oral consumption of aqueous saffron extract for three weeks was able to reduce intraocular pressure (IOP) in primary open-angle glaucoma [68], from a mean IOP of $12.9\pm 3.7$ mmHg to $10.9\pm 3.3$ mmHg after three weeks of intervention as compared to the control group (mean baseline IOP of $14.0\pm 2.5$ mmHg and $13.5\pm 2.3$ mmHg after three weeks). Hydrophilic saffron extracts standardized to 3% crocin was also found to decrease the neuroinflammation associated with increased IOP by decreasing microglion numbers and morphological signs of their activation including soma size and process retraction, as well as reversed ocular hypertension induced down-regulation of P2RY12, preventing retinal ganglion cell death in a glaucoma model [69].

An electroretinographic study has shown an increase in the amplitude of “a” and “b” waves in rabbits with experimental retinal dystrophy on the fifth day after receiving an injection of the saffron extract [70]. Several studies have evaluated the impact of oral saffron supplementation (daily dose between 20 and 50 mg) on vision-related parameters in AMD patients. Both short-term and longer-term follow-ups demonstrated that saffron supplementation improved visual functions, despite variable formulation, doses, intervention durations, test methods, and outcome measures in these studies [60, 71–76]. Toxicology research has found that saffron is safe for human consumption. The dose of 30 mg/day seems efficacious, and toxic effects have been reported with 5 g or more, with a lethal dose of approximately 20 g [57, 77], although long-term and large-scale research works are yet to be conducted to confirm its effect on human health.

1.3. Evidence for Bilberry

Bilberry (Vaccinium myrtillus L.) from Ericaceae is particularly rich in anthocyanins, such as delphinidin, malvidin, petunidin, cyanidin, and peonidin [78], and it has been shown that bilberry anthocyanins modulate oxidative stress defense enzyme heme oxygenase-1 (HO-1) and glutathione S-transferase-pi in human RPE cells [79]. Fursova et al. found that long-term (1.5 to 3 months) supplementation with bilberry extract to OXYS rats affected by accelerated aging, which is associated with high sensitivity to oxidative stress, was effective in preventing degeneration. Approximately 70% of the control OXYS rats were found to have macular degeneration after 3 months of treatment, while bilberry supplementation prevented impairments in the lenses and retina [80]. Furthermore, Osada et al. found that bilberry extract attenuates photo-induced apoptosis and visual dysfunction, which is most likely due to ROS reduction and subsequent endoplasmic reticulum stress attenuation in a murine model of the photo-stressed retina (750 mg/kg body weight) [81].

Oral consumption of bilberry extract supplement for 8 weeks has been shown to reduce the video display terminals (VDT) load-induced ocular fatigue sensation including ocular pain, eye heaviness, uncomfortable sensation, and foreign body sensation, as reduced critical flicker fusion (CFF) was alleviated after 8 weeks of intervention (95% confidence interval, 0.10-1.60; $P=0.023$), although no change in near point variation (NPA) was seen [82]. A longer period of consumption of bilberry extract (12 weeks) relieved the tonic accommodation of the ciliary muscle caused by VDT tasks and near-vision tasks, as the postload high-frequency component- (HFC-) 1 value at week 12 was significantly improved in the bilberry group ($P=0.017$), with significantly better task load at week 12 (ΔHFC-1) at week 12 ($P=0.049$) [83]. Bilberry extract may also alleviate the symptoms of dry eye disease (DED). The volume of tear secretion has shown improvement with bilberry extract supplement among subjects with DED over four weeks ($P=0.019$), as well as a significant improvement of biological antioxidant potential (BAP, $P=0.003$) and increased in modified BAP/diacron-reactive oxygen metabolites (d-ROMs) ratio, an indicator of overall balance between antioxidant potential and oxidative stress [84]. Apart from that, long-term consumption of bilberry extract can slow down axial elongation and control myopia progression in children with high myopia. Mean increase in spherical diopter was significantly lower $-10.8\pm 2.6$ D to $-11.2\pm 2.5$ D) compared to controls $-10.5\pm 2.6$ D to $-12.3\pm 2.6$ D). The increase in axial length was also significantly lesser ($23.7\pm 1.2$ mm to $23.9\pm 1.2$ mm) compared to the control ($23.9\pm 1.4$ mm to $24.8\pm 1.5$ mm) after 24 months [85]. A larger prospective study over a longer duration could reveal the true efficacy of these supplements against their cost.

1.4. Evidence for Beta-Carotene

Beta-carotene is a naturally occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities. As an antioxidant, beta-carotene inhibits free radical damage to DNA and is typically associated with eye health [86]. The Age-Related Eye Disease Study (AREDS) demonstrated that daily oral supplementation with antioxidative vitamins and minerals (vitamin C, vitamin E, beta-carotene, zinc, and copper) reduced the risk of developing advanced AMD by 25% at five years (odds ratio (OR), 0.72; 99% confidence interval (Cl), 0.52-0.98), as well as a significant reduction in rates of at least moderate visual acuity loss (OR, 0.73; 99% Cl, 0.54-0.99) [86]. However, a secondary analysis of the Age-Related Eye Disease Study 2 (AREDS2) shows that more lung cancers are diagnosed in participants with beta-carotene intake than those without [47]. Despite epidemiologic studies showing no association between dietary intake of vitamin A and reduced risk of AMD [43, 87], high levels of vitamin A, α-carotene, lycopene, and lutein intake were associated with low risk of cataract. Risk of nuclear cataract was lowest in people with high plasma concentration of α-carotene (OR, 0.5; 95% Cl, 0.3-0.9, $P=0.006$) or β-carotene (OR, 0.7; 95% Cl, 0.4-1.4, $P=0.033$), risk of cortical cataract was lowest in people with high plasma concentration of lycopene (OR, 0.4; 95% Cl, 0.2-0.8; $P=0.003$), and risk of posterior subcapsular cataract was lowest in people with high plasma concentration of lutein (OR, 0.5; 95% Cl, 0.2-1.0, $P=0.012$) [88].

2. Recommended Clinical Measurements of Antioxidant Effects on Vision

Given the fact that most antioxidants are not considered essential nutrients, most health authorities have yet to establish recommended daily intakes. Factors such as diet, gender, the existence of food intolerances, and the quantities of nutrients in foods also affect the daily average intakes of individuals. While it is more beneficial to consume whole food sources as they contain various other nutrients, supplements are available in the market for individuals who require greater quantities of specific nutrients that they might otherwise lack or insufficiently consume. Lutein supplements were available ranging from 5 mg to 25 mg, some with <5 mg of zeaxanthin, while recommended dose for eye health is 10 mg of lutein per day and 2 mg of zeaxanthin per day [28]. Daily intake of 50 mg of anthocyanins per day was recommended by the Chinese authorities to reduce oxidative stress levels and consequently the risk of degenerative diseases [89], where 50–88.5 mg of saffron extracts and 80–100 mg of bilberry extracts is available in each capsule. The recommended dietary allowance for vitamin A is 900 μg and 700 μg per day for adult males and females, respectively [90], with a tolerable upper intake level of 3000 μg per day.

Doses, regimes, methods of extraction, and drug interactions in the setting of a randomized trial must be elucidated to ensure the safety and efficacy of these treatments when given in combination. While we have presented the current evidence on the role of antioxidants on various ocular symptoms, such as dry eyes and presbyopia, one inherent limitation of these studies is the lack of objective outcomes, especially studies investigating presbyopia symptoms.

For example, a decrease in reduced antioxidant levels in the lens may promote the onset of presbyopia [91]. Hesperidin, a major flavonoid in citrus fruits and a natural antioxidant, was found to reduce the number of apoptotic cells, prevent premature cataract symptoms, maintain lens elasticity, and upregulate the mRNA expression of antioxidative enzymes in the selenite-induced cataract rat plasma and lens, hence delaying the formation of nuclear cataract [92] as well as the onset of presbyopia [93]. The challenges of such trials examining antioxidant effects include the influences of diet, environment, and various other patient characteristics, which are difficult to standardize.

Despite having some evidence for specific antioxidants with recommended doses impeding certain age-related eye diseases, there was a lack of extensive studies on the antioxidants’ effects on various ophthalmic diseases, and most studies available were concluded within a short period of time. The following table (Table 1) describes the clinical measurements which can be performed to understand the effectiveness of antioxidants on visual function and ophthalmic diseases.

Table 1

Antioxidant effects on vision and measurements to monitor the effects.

Antioxidant effects on	Clinical parameters to be measured	Rationale & method
Refractive error and accommodation	(i) Best-corrected functional near and distant visual acuity	The effect of antioxidants on disease prevention also has an overall impact on vision.
	(ii) The amplitude of accommodation and accommodative status	Bilberry extract influences the progression of myopia and changes in accommodation [83, 85].
Visual fatigue	(i) Subjective measures: visual fatigue questionnaires(ii) Objective measures of indices of visual fatigue: Accommodation parameters, critical flicker–fusion frequency (CFF), and blinking characteristics(iii) Workplace ergonomics questionnaire	Bilberry extract may reduce visual fatigue symptoms [82, 83]. Questionnaires are frequently used to identify self-reported visual fatigue symptoms [94–97]. Workplace ergonomics should take into consideration visual fatigue assessment, as it is one of the biggest confounding factors.
Ocular surface and dry eye	Diagnostic tests to assess and monitor dry eye according to the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) II report [92]:(i) Subjective measurement of symptoms: questionnaires such as the Ocular Surface Disease Index (OSDI)	Reduction in dry eye symptoms has been reported with intake of oral antioxidants containing bilberry extract [84]. Questionnaire instruments are often self-administered by the patient or research subject without input from the clinician or researcher [98–102].
	(ii) Tear film stability(a) Tear film breakup time (TBUT)(b) Noninvasive TBUT(c) Fluorescein tear breakup time (FBUT)	TBUT measures tear film stability. It is defined as the interval of time that elapses between a complete blink and the appearance of the first break in the tear film. The noninvasive technique (NIBUT) is preferred over the fluorescein technique (FBUT) [103].
	(iii) Tear volume(a) Schirmer test(b) Phenol red thread (PRT) test(c) Quantitative tear meniscus height and volume	Tear volume is quantified with the Schirmer test. The Schirmer test without anesthesia is well-standardized, providing an estimation of stimulated reflex tear flow. It is performed by folding a Schirmer paper strip at the notch and hooking the folded end over the temporal one-third of the lower lid margin. The score is the measured length of wetting from the notch, after five minutes. It can be performed with (a measurement of basal tear volume) and without topical anesthesia (a measurement of basal plus reflex tear volume)Alternatives to the Schirmer test are the phenol red thread (PRT) test. This test provides an indirect but realistic measure of the resting tear volume. The test is performed by hooking the folded end of the thread in the lower fornix for 15 seconds. When the phenol red meets the alkaline tears, it changes color from white to yellow-orange, yellow, and finally red. The thread is removed after 15 seconds and the red portion will be measured from the very tip regardless of the fold.The quantitative assessment of the tear menisci is, at present, the most direct approach to studying the tear film volume. The tear menisci serve as reservoirs, supplying tears to the precorneal tear film. Tear meniscus may take the form of a height or a cross-sectional volume metric.
	(iv) Damage to the ocular surface(a) Punctate staining of the ocular surface with topical sodium fluorescein	Punctate staining of the ocular surface is a feature of many ocular diseases and instilled dyes are used extensively in the diagnosis and management of dry eye. Ocular surface staining can be assessed using a slit-lamp biomicroscope following instillation of fluorescein dye and viewed under a cobalt blue filter.
	(v) Meibomian gland assessment(a) Meibum quantity, quality, and expressibility	Meibomian glands secrete meibum, which contains components of the lipid layer of the tear film. Meibum quantity, quality, and expressibility are thought to reflect meibomian gland function. The superficial location of the meibomian glands in the tarsal plates permits their anatomic features to be quantified by meibography and confocal microscopy.
	(vi) Objective dry eye measurement(a) Oculus Keratograph® 5M corneal topographer (Germany)	The Oculus Keratograph® 5 M corneal topographer is an advanced corneal topographer with a built-in real keratometer and a color camera. This permits optimized external imaging. Unique features of this instrument include examining the meibomian glands, NIBUT, and the tear meniscus height measurement and evaluating the lipid layer (source: https://www.oculus.de/us/ products/topography/keratograph-5m/oculus-keratograph-5m/). Parameters such as tear film stability, tear meniscus height, blink rate, and meibography can be recorded with this instrument. It provides a quick yet reliable dry eye analysis giving a more accurate clinical diagnosis.
Retinal structure, function, and microcirculation	(i) Optical coherence tomography (OCT) of the macula (non-invasive)	The literature indicates that antioxidant supplements with lutein, zeaxanthin, saffron, and beta-carotene have a reasonable probability of slowing the progression of retinal diseases [15–35, 38–45, 47–49, 53, 54, 66, 67, 69, 86]. OCT of the macula can display a cross-section of the macula, making it an invaluable noninvasive tool to objectively screen, diagnose and monitor AMD.
	(ii) OCT angiography (noninvasive)	OCT angiography is a newer imaging modality using the OCT platform. Real-time scanning of blood corpuscle movements in the retinal vessels produces 3-dimensional images of the macula and optic nerve head vasculature. In pathological conditions characterized by damage to blood vessels such as AMD and DR, this imaging technique also carries the potential for diagnosis, screening, and monitoring. While its advantages include no requirement for peripheral venous canulation and invasive dyes, its effectiveness as compared to conventional angiography is still being investigated.
	(iii) Fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) (invasive)	The advantages of conventional dye angiography over OCTA include the ability to determine leakage. While the OCTA can show abnormal vasculature progression, the FFA and ICGA are still necessary to determine the presence of leakage and diagnose polyps in polypoidal choroidal vasculopathy, a subset of AMD. However, it must be used with caution among patients with renal impairment, those who are pregnant or have a history of anaphylaxis.
	(iv) Multifocal electroretinogram (mfERG)	mfERG is an objective test for retinal function by measuring retinal conduction. mfERG can be performed according to guidelines from the International Society for Clinical Electrophysiology of Vision (ISCEV) [104]. The recording is performed with full correction for near vision and dilated pupils. The standard measurement for mfERG amplitude and timing is the amplitude measured from the trough of N1 (first negative deflection) to the peak of P1 (positive peak after N1), and the peak time of P1, respectively.
Optic nerve assessment for structure, function, microcirculation, and risk factor for damage.	(i) Tonometry for IOP measurement	The IOP should be measured as the saffron extract has been reported to cause IOP reduction in glaucoma patients [68]. The IOP is influenced by various factors, including the patient’s position during measurement, central corneal thickness, corneal diameter and curvature, the rigidity of the cornea, and the cornea’s state of hydration. At present, the gold standard of IOP measurement is the Goldmann applanation tonometry (GAT). Several new devices for IOP measurement have been developed, including noncontact tonometry, the Tono-Pen (Reichert, US), the ICare tonometer (Finland), dynamic contour tonometry (Ziemer, Switzerland), TGDc-01 tonometry (Rjazan State Instrument Making, Russia), and the ocular response analyzer (Reichert, US).
	(ii) Structural test: OCT of the optic nerve	OCT of the peripapillary retinal nerve fiber layer (RNFL) is also useful to diagnose glaucomatous optic neuropathy by virtue of the characteristic loss of the RNFL thickness, particularly at the superior and inferior quadrants of the disc. It is also useful to monitor the progression of optic nerve damage in early to moderate glaucoma. It is less useful in advanced glaucoma, being better monitored by automated perimetry at more advanced stages.
	(iii) Automated perimetry, e.g., Humphrey visual field analyzer (Carl Zeiss Meditech, US)	Automated perimetry is an objective test to map out the visual field defect sustained from various types of optic neuropathy, including glaucoma. Apart from eliciting the characteristic visual field defects, it is also used for characterizing glaucoma into mild, moderate, and severe stages. This allows appropriate and customized treatment of the disease.

3. Conclusion

In conclusion, prevention and treatment of age-related eye diseases with antioxidant substances and other supplements including polyphenol, xanthophyll carotenoids, anthocyanins, and other medicinal plants and natural products [105] have shown promising effects for a multitude of eye diseases. While polyphenols and xanthophyll carotenoids are the most commonly reported natural products used for AMD treatment with positive results, more research and clinical trials are necessary to understand their mechanisms of action.

Authors’ Contributions

Writing—original draft preparation was done by PPC and PJW. Writing—review and editing was done by MLCB, RO, MM, and NMD. All authors have read and agreed to the published version of the manuscript.

References

[1] S. R. Flaxman, R. R. A. Bourne, S. Resnikoff, P. Ackland, T. Braithwaite, M. V. Cicinelli, D. Aditi, J. B. Jonas, J. Keeffe, J. H. Kempen, J. Leasher, H. Limburg, K. Naidoo, K. Pesudovs, A. Silvester, G. A. Stevens, N. Tahhan, T. Y. Wong, H. R. Taylor, Vision Loss Expert Group of the Global Burden of Disease Study, "Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis," Lancet Glob. Health, vol. 5 no. 12, pp. e1221-e1234, DOI: 10.1016/S2214-109X(17)30393-5, 2017.

[2] M. Nita, A. Grzybowski, "The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults," Oxidative Medicine and Cellular Longevity, vol. 2016,DOI: 10.1155/2016/3164734, 2016.

[3] G. Tezel, "Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences," Progress in Retinal and Eye Research, vol. 25 no. 5, pp. 490-513, DOI: 10.1016/j.preteyeres.2006.07.003, 2006.

[4] K. A. Weikel, C. J. Chiu, A. Taylor, "Nutritional modulation of age-related macular degeneration," Molecular Aspects of Medicine, vol. 33 no. 4, pp. 318-375, DOI: 10.1016/j.mam.2012.03.005, 2012.

[5] O. Sideri, K. T. Tsaousis, H. J. Li, M. Viskadouraki, I. T. Tsinopoulos, "The potential role of nutrition on lens pathology: a systematic review and meta-analysis," Survey of Ophthalmology, vol. 64 no. 5, pp. 668-678, DOI: 10.1016/j.survophthal.2019.03.003, 2019.

[6] E. Loskutova, C. O’Brien, I. Loskutov, J. Loughman, "Nutritional supplementation in the treatment of glaucoma: a systematic review," Survey of Ophthalmology, vol. 64 no. 2, pp. 195-216, DOI: 10.1016/j.survophthal.2018.09.005, 2019.

[7] C. Li, X. Miao, F. Li, S. Wang, Q. Liu, Y. Wang, J. Sun, "Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy," Oxidative Medicine and Cellular Longevity, vol. 2017,DOI: 10.1155/2017/9702820, 2017.

[8] E. J. Johnson, "Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan," Nutrition Reviews, vol. 72 no. 9, pp. 605-612, DOI: 10.1111/nure.12133, 2014.

[9] D. M. Snodderly, "Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins," The American Journal of Clinical Nutrition, vol. 62 no. 6, pp. 1448S-1461S, DOI: 10.1093/ajcn/62.6.1448S, 1995.

[10] J. T. Landrum, R. A. Bone, "Mechanistic evidence for eye diseases and carotenoids," Carotenoids in Health and Disease, pp. 445-472, DOI: 10.1201/9780203026649.ch20, 2004.

[11] F. M. Barker, D. M. Snodderly, E. J. Johnson, W. Schalch, W. Koepcke, J. Gerss, M. Neuringer, "Nutritional manipulation of primate retinas, V: effects of lutein, zeaxanthin, and n-3 fatty acids on retinal sensitivity to blue-light-induced damage," Investigative Ophthalmology & Visual Science, vol. 52 no. 7, pp. 3934-3942, DOI: 10.1167/iovs.10-5898, 2011.

[12] P. S. Bernstein, F. Khachik, L. S. Carvalho, G. J. Muir, D. Y. Zhao, N. B. Katz, "Identification and quantitation of carotenoids and their metabolites in the tissues of the human eyes," Experimental Eye Research, vol. 72, pp. 215-223, 2011.

[13] Q. Bian, S. Gao, J. Zhou, J. Qin, A. Taylor, E. J. Johnson, G. Tang, J. R. Sparrow, D. Gierhart, F. Shang, "Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells," Free Radical Biology & Medicine, vol. 53 no. 6, pp. 1298-1307, DOI: 10.1016/j.freeradbiomed.2012.06.024, 2012.

[14] M. Sasaki, Y. Ozawa, T. Kurihara, K. Noda, Y. Imamura, S. Kobayashi, S. Ishida, K. Tsubota, "Neuroprotective effect of an antioxidant, lutein, during retinal inflammation," Investigative Ophthalmology & Visual Science, vol. 50 no. 3, pp. 1433-1439, DOI: 10.1167/iovs.08-2493, 2009.

[15] T. T. J. M. Berendschot, Y. Tian, I. Murray, M. Makridaki, "Lutein supplementation leads to a decreased level of circulating complement factors," Investigative Ophthalmology & Visual Science, vol. 54, 2013.

[16] Y. Tian, A. Kijlstra, C. A. B. Webers, T. T. J. M. Berendschot, "Lutein and factor D: two intriguing players in the field of age-related macular degeneration," Archives of Biochemistry and Biophysics, vol. 572, pp. 49-53, DOI: 10.1016/j.abb.2015.01.019, 2015.

[17] Age-Related Eye Disease Study Research Group, "The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study AREDS report no. 22," Archives of Ophthalmology, vol. 125, pp. 1225-1232, 2007.

[18] S. Beatty, I. J. Murray, D. B. Henson, D. Carden, H. H. Koh, M. E. Boulton, "Macular pigment and risk for age-related macular degeneration in subjects from a northern European population," Investigative Ophthalmology & Visual Science, vol. 42 no. 2, pp. 439-446, 2001.

[19] J. M. Nolan, J. Stack, E. O’Connell, S. Beatty, "The relationships between macular pigment optical density and its constituent carotenoids in diet and serum," Investigative Ophthalmology & Visual Science, vol. 48 no. 2, pp. 571-582, DOI: 10.1167/iovs.06-0864, 2007.

[20] R. Liu, T. Wang, B. Zhang, L. Qin, C. Wu, Q. Li, L. Ma, "Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration," Investigative Ophthalmology & Visual Science, vol. 56 no. 1, pp. 252-258, DOI: 10.1167/iovs.14-15553, 2015.

[21] L. Ma, R. Liu, J. H. Du, T. Liu, S. S. Wu, X. H. Liu, "Lutein, zeaxanthin and meso-zeaxanthin supplementation associated with macular pigment optical density," Nutrients, vol. 8 no. 7,DOI: 10.3390/nu8070426, 2016.

[22] G. Weigert, S. Kaya, B. Pemp, S. Sacu, M. Lasta, R. M. Werkmeister, N. Drargostinoff, C. Simader, G. Garhöfer, U. Schmidt-Erfurth, L. Schmetterer, "Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration," Investigative Ophthalmology & Visual Science, vol. 52 no. 11, pp. 8174-8178, DOI: 10.1167/iovs.11-7522, 2011.

[23] I. J. Murray, M. Makridaki, R. L. P. van der Veen, D. Carden, N. R. A. Parry, T. T. J. M. Berendschot, "Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study," Investigative Ophthalmology & Visual Science, vol. 54 no. 3, pp. 1781-1788, DOI: 10.1167/iovs.12-10715, 2013.

[24] M. M. Moschos, M. Dettoraki, M. Tsatsos, G. Kitsos, C. Kalogeropoulos, "Effect of carotenoids dietary supplementation on macular function in diabetic patients," Eye Vision, vol. 4, 2017.

[25] Y. Yao, Q. H. Qiu, X. W. Wu, Z. Y. Cai, S. Xu, X. Q. Liang, "Lutein supplementation improves visual performance in Chinese drivers: 1-year randomized, double-blind, placebo-controlled study," Nutrition, vol. 29 no. 7-8, pp. 958-964, DOI: 10.1016/j.nut.2012.10.017, 2013.

[26] J. A. Mares, "Relationships of lutein and zeaxanthin to age-related macular degeneration: epidemiological evidence," Carotenoids and Retinal Disease, pp. 63-74, DOI: 10.1201/b15556-5, 2013.

[27] N. I. Krinsky, J. T. Landrum, R. A. Bone, "Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye," Annual Review of Nutrition, vol. 23 no. 1, pp. 171-201, DOI: 10.1146/annurev.nutr.23.011702.073307, 2003.

[28] B. R. Hammond, L. M. Fletcher, F. Roos, J. Wittwer, W. Schalch, "A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast," Investigative Ophthalmology & Visual Science, vol. 55 no. 12, pp. 8583-8589, DOI: 10.1167/iovs.14-15573, 2014.

[29] B. Yu, J. Wang, P. M. Suter, R. M. Russell, M. A. Grusak, Y. Wang, Z. Wang, S. Yin, G. Tang, "Spirulina is an effective dietary source of zeaxanthin to humans," The British Journal of Nutrition, vol. 108 no. 4, pp. 611-619, DOI: 10.1017/S0007114511005885, 2012.

[30] J. M. Nolan, R. Power, J. Stringham, J. Dennison, J. Stack, D. Kelly, R. Moran, K. O. Akuffo, L. Corcoran, S. Beatty, "Enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease: central retinal enrichment supplementation trials – report 1," Investigative Ophthalmology & Visual Science, vol. 57 no. 7, pp. 3429-3439, DOI: 10.1167/iovs.16-19520, 2016.

[31] B. Olmedilla, F. Granado, I. Blanco, M. Vaquero, "Lutein, but not α -tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study," Nutrition, vol. 19 no. 1, pp. 21-24, DOI: 10.1016/S0899-9007(02)00861-4, 2003.

[32] J. M. Stringham, B. R. Hammond, "Macular pigment and visual performance under glare conditions," Optometry and Vision Science, vol. 85 no. 2, pp. 82-88, DOI: 10.1097/OPX.0b013e318162266e, 2008.

[33] H. T. V. Vu, L. Robman, A. Hodge, C. A. McCarty, H. R. Taylor, "Lutein and zeaxanthin and the risk of cataract: the Melbourne Visual Impairment Project," Investigative Ophthalmology & Visual Science, vol. 47 no. 9, pp. 3783-3786, DOI: 10.1167/iovs.05-0587, 2006.

[34] B.-J. Hu, Y.-N. Hu, S. Lin, W.-J. Ma, X.-R. Li, "Application of lutein and zeaxanthin in nonproliferative diabetic retinopathy," International Journal of Ophthalmology, vol. 4 no. 3, pp. 303-306, DOI: 10.3980/j.issn.2222-3959.2011.03.19, 2011.

[35] S. Gao, T. Qin, Z. Liu, M. A. Caceres, C. F. Ronchi, O. C.-Y. Chen, K.-J. Yeum, A. Taylor, J. B. Blumberg, Y. Liu, F. Shang, "Lutein and zeaxanthin supplementation reduces H 2 O 2 -induced oxidative damage in human lens epithelial cells," Molecular Vision, vol. 17, pp. 3180-3190, 2011.

[36] K. J. Meyers, E. J. Johnson, P. S. Bernstein, S. K. Iyengar, C. D. Engelman, C. K. Karki, Z. Liu, R. P. Igo, B. Truitt, M. L. Klein, D. M. Snodderly, B. A. Blodi, K. M. Gehrs, G. E. Sarto, R. B. Wallace, J. Robinson, E. S. LeBlanc, G. Hageman, L. Tinker, J. A. Mares, "Genetic determinants of macular pigments in women of the carotenoids in age-related eye disease study," Investigative Ophthalmology & Visual Science, vol. 54 no. 3, pp. 2333-2345, DOI: 10.1167/iovs.12-10867, 2013.

[37] K. J. Meyers, J. A. Mares, R. P. Igo, B. Truitt, Z. Liu, A. E. Millen, M. Klein, E. J. Johnson, C. D. Engelman, C. K. Karki, B. Blodi, K. Gehrs, L. Tinker, R. Wallace, J. Robinson, E. S. LeBlanc, G. Sarto, P. S. Bernstein, J. P. SanGiovanni, S. K. Iyengar, "Genetic evidence for role of carotenoids in age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS)," Investigative Ophthalmology & Visual Science, vol. 55 no. 1, pp. 587-599, DOI: 10.1167/iovs.13-13216, 2014.

[38] L. Ho, R. van Leeuwen, J. C. Witteman, C. M. van Duijn, A. G. Uitterlinden, A. Hofman, P. T. V. M. de Jong, J. R. Vingerling, C. C. W. Klaver, "Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ω -3 fatty acids: the Rotterdam study," Archives of Ophthalmology, vol. 129 no. 6, pp. 758-766, DOI: 10.1001/archophthalmol.2011.141, 2011.

[39] J. J. Wang, G. H. Buitendijk, E. Rochtchina, K. E. Lee, B. E. Klein, C. M. van Duijn, V. M. Flood, S. M. Meuer, J. Attia, C. Myers, E. G. Holliday, A. G. Tan, W. T. Smith, S. K. Iyengar, P. T. V. M. de Jong, A. Hofman, J. R. Vingerling, P. Mitchell, R. Klein, C. C. W. Klaver, "Genetic susceptibility, dietary antioxidants, and long-term incidence of age- related macular degeneration in two populations," Ophthalmology, vol. 121 no. 3, pp. 667-675, DOI: 10.1016/j.ophtha.2013.10.017, 2014.

[40] K. J. Meyers, Z. Liu, A. E. Millen, S. K. Iyengar, B. A. Blodi, E. Johnson, D. M. Snodderly, M. L. Klein, K. M. Gehrs, L. Tinker, G. E. Sarto, J. Robinson, R. B. Wallace, J. A. Mares, "Joint associations of diet, lifestyle, and genes with age-related macular degeneration," Ophthalmology, vol. 122 no. 11, pp. 2286-2294, DOI: 10.1016/j.ophtha.2015.07.029, 2015.

[41] J. A. Mares-Perlman, A. I. Fisher, R. Klein, M. Palta, G. Block, A. E. Millen, J. D. Wright, "Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey," American Journal of Epidemiology, vol. 153 no. 5, pp. 424-432, DOI: 10.1093/aje/153.5.424, 2001.

[42] S. M. Moeller, N. Parekh, L. Tinker, C. Ritenbaugh, B. Blodi, R. B. Wallace, J. A. Mares, CAREDS Research Study Group, "Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS)," Archives of Ophthalmology, vol. 124 no. 8, pp. 1151-1162, DOI: 10.1001/archopht.124.8.1151, 2006.

[43] J. M. Seddon, U. A. Ajani, R. D. Sperduto, R. Hiller, N. Blair, T. C. Burton, M. D. Farber, E. S. Gragoudas, J. Haller, D. T. Miller, L. A. Yannuzzi, W. Willett, "Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group," Journal of the American Medical Association, vol. 272 no. 18, pp. 1413-1420, 1994.

[44] J. Wu, E. Cho, W. C. Willett, S. M. Sastry, D. A. Schaumberg, "Intakes of lutein, zeaxanthin, and other carotenoids and age-related macular degeneration during 2 decades of prospective follow-up," JAMA. Ophthalmology, vol. 133 no. 12, pp. 1415-1424, DOI: 10.1001/jamaophthalmol.2015.3590, 2015.

[45] K. O. Akuffo, J. M. Nolan, A. N. Howard, R. Moran, J. Stack, R. Klein, B. E. Klein, S. M. Meuer, S. Sabour-Pickett, D. I. Thurnham, S. Beatty, "Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration," Eye (London, England), vol. 29 no. 7, pp. 902-912, DOI: 10.1038/eye.2015.64, 2015.

[46] S. Beatty, U. Chakravarthy, J. M. Nolan, K. A. Muldrew, J. V. Woodside, F. Denny, M. R. Stevenson, "Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration," Ophthalmology, vol. 120 no. 3, pp. 600-606, DOI: 10.1016/j.ophtha.2012.08.040, 2013.

[47] "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration," Journal of the American Medical Association, vol. 309 no. 19, pp. 2005-2015, DOI: 10.1001/jama.2013.4997, 2013.

[48] E. Y. Chew, T. E. Clemons, J. P. SanGiovanni, R. P. Danis, F. L. Ferris, M. J. Elman, A. N. Antoszyk, A. J. Ruby, D. Orth, S. B. Bressler, G. E. Fish, "Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3," JAMA Ophthalmology, vol. 132 no. 2, pp. 142-149, DOI: 10.1001/jamaophthalmol.2013.7376, 2014.

[49] E. J. Johnson, J. E. Maras, H. M. Rasmussen, K. L. Tucker, "Intake of lutein and zeaxanthin differ with age, sex, and ethnicity," Journal of the American Dietetic Association, vol. 110 no. 9, pp. 1357-1362, DOI: 10.1016/j.jada.2010.06.009, 2010.

[50] Y. P. Jang, J. L. Zhou, K. Nakanishi, J. R. Sparrow, "Anthocyanins protect against A2E photooxidation and membrane permeabilization in retinal pigment epithelial cells," Photochemistry and Photobiology, vol. 81 no. 3, pp. 529-536, DOI: 10.1562/2004-12-14-RA-402.1, 2005.

[51] L. Fernández-Sánchez, P. Lax, A. Noailles, A. Angulo, V. Maneu, N. Cuenca, "Natural compounds from saffron and bear bile prevent vision loss and retinal degeneration," Molecules, vol. 20 no. 8, pp. 13875-13893, DOI: 10.3390/molecules200813875, 2015.

[52] S. K. Gupta, B. Kumar, B. P. Srinivasan, T. C. Nag, S. Srivastava, R. Saxena, A. Aggarwal, "Retinoprotective effects of Moringa oleifera via antioxidant, anti-inflammatory, and anti-angiogenic mechanisms in streptozotocin-induced diabetic rats," Journal of Ocular Pharmacology and Therapeutics, vol. 29 no. 4, pp. 419-426, DOI: 10.1089/jop.2012.0089, 2013.

[53] H. L. Ramkumar, J. Tuo, D. F. Shen, J. Zhang, X. Cao, E. Y. Chew, C.-C. Chan, "Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background," The Journal of Nutrition, vol. 143 no. 7, pp. 1129-1135, DOI: 10.3945/jn.112.169649, 2013.

[54] W. Kalt, A. Hanneken, P. Milbury, F. Tremblay, "Recent research on polyphenolics in vision and eye health," Journal of Agricultural and Food Chemistry, vol. 58 no. 7, pp. 4001-4007, DOI: 10.1021/jf903038r, 2010.

[55] R. J. Williams, J. P. E. Spencer, C. Rice-Evans, "Flavonoids: antioxidants or signalling molecules?," Free Radical Biology & Medicine, vol. 36 no. 7, pp. 838-849, DOI: 10.1016/j.freeradbiomed.2004.01.001, 2004.

[56] T. Tsuda, "Dietary anthocyanin-rich plants: biochemical basis and recent progress in health benefits studies," Molecular Nutrition & Food Research, vol. 56 no. 1, pp. 159-170, DOI: 10.1002/mnfr.201100526, 2012.

[57] E. Christodoulou, N. P. Kadoglou, N. Kostomitsopoulos, G. Valsami, "Saffron: a natural product with potential pharmaceutical applications," The Journal of Pharmacy and Pharmacology, vol. 67 no. 12, pp. 1634-1649, DOI: 10.1111/jphp.12456, 2015.

[58] S. Rahaiee, S. Moini, M. Hashemi, S. A. Shojaosadati, "Evaluation of antioxidant activities of bioactive compounds and various extracts obtained from saffron (Crocus sativus L): a review," Journal of Food Science and Technology, vol. 52 no. 4, pp. 1881-1888, DOI: 10.1007/s13197-013-1238-x, 2015.

[59] G. K. Broadhead, A. Chang, J. R. Grigg, P. McCluskey, "Efficacy and safety of saffron supplementation: current clinical findings," Critical Reviews in Food Science and Nutrition, vol. 56 no. 16, pp. 2767-2776, DOI: 10.1080/10408398.2013.879467, 2016.

[60] S. Di Marco, V. Carnicelli, N. Fraceschini, M. Di Paolo, M. Piccardi, S. Bisti, B. Falsini, "Saffron: a multitask neuroprotective agent for retinal degenerative diseases," Antioxidants (Basel), vol. 8 no. 7,DOI: 10.3390/antiox8070224, 2019.

[61] C. D. Kanakis, P. A. Tarantilis, C. Pappas, J. Bariyanga, H. A. Tajmir-Riahi, M. G. Polissiou, "An overview of structural features of DNA and RNA complexes with saffron compounds: models and antioxidant activity," Journal of Photochemistry and Photobiology B: Biology, vol. 95 no. 3, pp. 204-212, DOI: 10.1016/j.jphotobiol.2009.03.006, 2009.

[62] K. N. Nam, Y.-M. Park, H.-J. Jung, J. Y. Lee, B. D. Min, S.-U. Park, W.-S. Jung, K.-H. Cho, J.-H. Park, I. Kang, J.-W. Hong, E. H. Lee, "Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells," European Journal of Pharmacology, vol. 648 no. 1-3, pp. 110-116, DOI: 10.1016/j.ejphar.2010.09.003, 2010.

[63] M. Yamauchi, K. Tsuruma, S. Imai, T. Nakanishi, N. Umigai, M. Shimazawa, H. Hara, "Crocetin prevents retinal degeneration induced by oxidative and endoplasmic reticulum stresses via inhibition of caspase activity," European Journal of Pharmacology, vol. 650 no. 1, pp. 110-119, DOI: 10.1016/j.ejphar.2010.09.081, 2011.

[64] Y. Ohno, T. Nakanishi, N. Umigai, K. Tsuruma, M. Shimazawa, H. Hara, "Oral administration of crocetin prevents inner retinal damage induced by N -methyl-d-aspartate in mice," European Journal of Pharmacology, vol. 690 no. 1-3, pp. 84-89, DOI: 10.1016/j.ejphar.2012.06.035, 2012.

[65] E. Tamaddonfard, A. A. Farshid, K. Eghdami, F. Samadi, A. Erfanparast, "Comparison of the effects of crocin, safranal and diclofenac on local inflammation and inflammatory pain responses induced by carrageenan in rats," Pharmacological Reports, vol. 65 no. 5, pp. 1272-1280, DOI: 10.1016/S1734-1140(13)71485-3, 2013.

[66] B. Xuan, Y. H. Zhou, N. Li, Z. D. Min, G. C. Chiou, "Effects of crocin analogs on ocular blood flow and retinal function," Journal of Ocular Pharmacology and Therapeutics, vol. 15 no. 2, pp. 143-152, DOI: 10.1089/jop.1999.15.143, 1999.

[67] M. Giaccio, "Crocetin from saffron: an active component of an ancient spice," Critical Reviews in Food Science and Nutrition, vol. 44 no. 3, pp. 155-172, DOI: 10.1080/10408690490441433, 2004.

[68] M. H. J. Bonyadi, S. Yazdani, S. Saadat, "The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study," BMC Complementary and Alternative Medicine, vol. 14, 2014.

[69] J. A. Fernandez-Albarral, A. I. Ramires, R. De Hoz, N. Lopez-Villarin, "Neuroprotective and anti-inflammatory effects of a hydrophilic saffron extract in a model of glaucoma," International Journal of Molecular Sciences, vol. 20, 2019.

[70] P. Shukurova, R. Babaev, "A study into the effectiveness of the application of saffron extract in ocular pathologies in experiment," Georgian Medical News, vol. 182, pp. 38-42, 2010.

[71] B. Falsini, M. Piccardi, A. Minnella, C. Savastano, E. Capoluongo, A. Fadda, E. Balestrazzi, R. Maccarone, S. Bisti, "Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration," Investigative Ophthalmology & Visual Science, vol. 51 no. 12, pp. 6118-6124, DOI: 10.1167/iovs.09-4995, 2010.

[72] A. Lashay, G. Sadough, E. Ashrafi, M. Lashay, M. Movassat, S. Akhondzadeh, "Short-term outcomes of saffron supplementation in patients with age-related macular degeneration: a double-blind, placebo-controlled, randomized trial," Medical Hypothesis, Discovery and Innovation in Ophthalmology, vol. 5 no. 1, pp. 32-38, 2016.

[73] A. Riazi, Y. Panahi, A. A. Alishiri, M. A. Hosseini, A. A. K. Zarchi, A. Sahebkar, "The impact of saffron (Crocus sativus) supplementation on visual function in patients with dry age-related macular degeneration," Italian Journal of Medicine, vol. 11, pp. 196-201, 2017.

[74] G. K. Broadhead, J. R. Grigg, P. McCluskey, T. Hong, T. E. Schlub, A. A. Chang, "Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 257 no. 1, pp. 31-40, DOI: 10.1007/s00417-018-4163-x, 2019.

[75] M. Piccardi, D. Marangoni, A. M. Minnella, M. C. Savastano, P. Valentini, L. Ambrosio, E. Capoluongo, R. Maccarone, S. Bisti, B. Falsini, "A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function," Evidence-based Complementary and Alternative Medicine, vol. 2012,DOI: 10.1155/2012/429124, 2012.

[76] D. Marangoni, B. Falsini, M. Piccardi, L. Ambrosio, A. M. Minnella, M. C. Savastano, S. Bisti, R. Maccarone, A. Fadda, E. Mello, P. Concolino, E. Capoluongo, "Functional effect of saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report," Journal of Translational Medicine, vol. 11 no. 1,DOI: 10.1186/1479-5876-11-228, 2013.

[77] A. H. Mohamadpour, Z. Ayati, M. R. Parizadeh, O. Rajbai, H. Hosseinzadeh, "Safety evaluation of crocin (a constituent of saffron) tablets in healthy volunteers," Iranian Journal of Basic Medical Sciences, vol. 16 no. 1, pp. 39-46, 2013.

[78] Q. You, B. Wang, F. Chen, Z. Huang, X. Wang, P. G. Luo, "Comparison of anthocyanins and phenolics in organically and conventionally grown blueberries in selected cultivars," Food Chemistry, vol. 125 no. 1, pp. 201-208, DOI: 10.1016/j.foodchem.2010.08.063, 2011.

[79] P. E. Milbury, B. Graf, J. M. Curran-Celentano, J. B. Blumberg, "Bilberry (Vaccinium myrtillus) anthocyanins modulate heme oxygenase-1 and glutathione S-transferase-pi expression in ARPE-19 cells," Investigative Ophthalmology & Visual Science, vol. 48 no. 5, pp. 2343-2349, DOI: 10.1167/iovs.06-0452, 2007.

[80] A. Z. H. Fursova, O. G. Gesarevich, A. M. Gonchar, N. A. Trofimova, N. G. Kolosova, "Dietary supplementation with bilberry extract prevents macular degeneration and cataracts in senesce-accelerated OXYS rats," Advances in Gerontology, vol. 16, pp. 76-79, 2005.

[81] H. Osada, T. Okamoto, H. Kawashima, E. Toda, S. Miyake, N. Nagai, S. Kobayashi, K. Tsubota, Y. Ozawa, "Neuroprotective effect of bilberry extract in a murine model of photo-stressed retina," PLoS One, vol. 12 no. 6,DOI: 10.1371/journal.pone.0178627, 2017.

[82] Y. Ozawa, M. Kawashima, S. Inoue, E. Inagaki, A. Suzuki, E. Ooe, S. Kobayashi, K. Tsubota, "Bilberry extract supplementation for preventing eye fatigue in video display terminal workers," The Journal of Nutrition, Health & Aging, vol. 19 no. 5, pp. 548-554, DOI: 10.1007/s12603-014-0573-6, 2015.

[83] M. Kosehira, N. Machida, N. A. Kitaichi, "A 12-week-long intake of bilberry extract (Vaccinium myrtillus L.) improved objective findings of ciliary muscle contraction of the eye: a randomized, double-blind, placebo-controlled, parallel-group comparison trial," Nutrients, vol. 12 no. 3,DOI: 10.3390/nu12030600, 2020.

[84] A. Riva, S. Togni, F. Franceschi, S. Kawada, Y. Inaba, R. Eggenhoffner, L. Giacomelli, "The effect of a natural, standardized bilberry extract (Mirtoselect®) in dry eye: a randomized, double blinded, placebo-controlled trial," European Review for Medical and Pharmacological Sciences, vol. 21 no. 10, pp. 2518-2525, 2017.

[85] I. A. N. Omar, "Effect of bilberry extract on slowing high-myopia progression in children: 2-year follow-up study," Clinical Ophthalmology, vol. Volume 12, pp. 2575-2579, DOI: 10.2147/OPTH.S187949, 2018.

[86] Age-Related Eye Disease Study Research Group, "A randomized, placebo-controlled, clinical trial of High-Dose Supplementation With vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision Loss," Archives of Ophthalmology, vol. 119 no. 10, pp. 1417-1436, DOI: 10.1001/archopht.119.10.1417, 2001.

[87] C. Delcourt, J. P. Cristol, F. Tessier, C. L. Léger, B. Descomps, L. Papoz, "Age-related macular degeneration and antioxidant status in the POLA study," Archives of Ophthalmology, vol. 117 no. 10, pp. 1384-1390, DOI: 10.1001/archopht.117.10.1384, 1999.

[88] C. R. Gale, N. F. Hall, D. I. W. Phillips, C. N. Martyn, "Plasma antioxidant vitamins and carotenoids and age-related cataract," Ophthalmology, vol. 108 no. 11, pp. 1992-1998, DOI: 10.1016/S0161-6420(01)00833-8, 2001.

[89] Chinese Nutrition Society, Chinese DRIs Handbook, 2013.

[90] N. Pescosolido, A. Barbato, R. Giannotti, C. Komaiha, F. Lenarduzzi, "Age-related changes in the kinetics of human lenses: prevention of the cataract," International Journal of Ophthalmology, vol. 9 no. 10, pp. 1506-1517, 2016.

[91] Y. Nakazawa, M. Aoki, S. Ishiwa, N. Morishita, S. Endo, N. Nagai, N. Yamamoto, M. Funakoshi-Tago, H. Tamura, "Oral intake of α -glucosyl-hesperidin ameliorates selenite-induced cataract formation," Molecular Medicine Reports, vol. 21 no. 3, pp. 1258-1266, DOI: 10.3892/mmr.2020.10941, 2020.

[92] Y. Nakazawa, M. Aoki, Y. Doki, N. Morishita, S. Endo, N. Nagai, M. Funakoshi-Tago, H. Tamura, "Oral consumption of α -glucosyl-hesperidin could prevent lens hardening, which causes presbyopia," Biochemistry and Biophysics Reports, vol. 25,DOI: 10.1016/j.bbrep.2020.100885, 2021.

[93] Institute of Medicine Food and Nutrition Board, Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, 2001.

[94] J. R. Hayes, J. E. Sheedy, J. A. Stelmack, C. A. Heaney, "Computer use, symptoms, and quality of life," Optometry and Vision Science, vol. 84 no. 8, pp. E738-E755, DOI: 10.1097/OPX.0b013e31812f7546, 2007.

[95] M. González-Pérez, R. Susi, B. Antona, A. Barrio, E. González, "The computer-vision symptom scale (CVSS17): development and initial validation," Investigative Ophthalmology & Visual Science, vol. 55 no. 7, pp. 4504-4511, DOI: 10.1167/iovs.13-13818, 2014.

[96] M. del Mar Seguí, J. Cabrero-García, A. Crespo, J. Verdú, E. Ronda, "A reliable and valid questionnaire was developed to measure computer vision syndrome at the workplace," Journal of Clinical Epidemiology, vol. 68 no. 6, pp. 662-673, DOI: 10.1016/j.jclinepi.2015.01.015, 2015.

[97] J. S. Wolffsohn, R. Arita, R. Chalmers, A. Djalilian, M. Dogru, K. Dumbleton, P. K. Gupta, P. Karpecki, S. Lazreg, H. Pult, B. D. Sullivan, A. Tomlinson, L. Tong, E. Villani, K. C. Yoon, L. Jones, J. P. Craig, "TFOS DEWS II diagnostic methodology report," The Ocular Surface, vol. 15 no. 3, pp. 539-574, DOI: 10.1016/j.jtos.2017.05.001, 2017.

[98] R. M. Schiffman, M. D. Christianson, G. Jacobsen, J. D. Hirsch, B. L. Reis, "Reliability and validity of the ocular surface disease index," Archives of Ophthalmology, vol. 118 no. 5, pp. 615-621, DOI: 10.1001/archopht.118.5.615, 2000.

[99] R. L. Chalmers, C. G. Begley, B. Caffery, "Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses," Contact Lens & Anterior Eye, vol. 33 no. 2, pp. 55-60, DOI: 10.1016/j.clae.2009.12.010, 2010.

[100] L. Abetz, K. Rajagopalan, P. Mertzanis, C. Begley, R. Barnes, R. Chalmers, the impact of dry eye on everyday life (IDEEL) Study Group, "Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients," Health and Quality of Life Outcomes, vol. 9 no. 1,DOI: 10.1186/1477-7525-9-111, 2011.

[101] C. W. McMonnies, A. Ho, "Responses to a dry eye questionnaire from a normal population," Journal of the American Optometric Association, vol. 58 no. 7, pp. 588-591, 1987.

[102] D. A. Schaumberg, A. Gulati, W. D. Mathers, T. Clinch, M. A. Lemp, J. D. Nelson, G. N. Foulks, R. Dana, "Development and validation of a short global dry eye symptom index," The Ocular Surface, vol. 5 no. 1, pp. 50-57, DOI: 10.1016/S1542-0124(12)70053-8, 2007.

[103] A. J. Bron, M. B. Abelson, G. Ousler, E. Pearce, A. Tomlinson, N. Yokoi, J. A. Smith, C. Begley, B. Caffery, K. Nchols, D. Schaumberg, O. Schein, M. Calonge, C. Baudouin, E. Goto, F. Grus, J. Paugh, "Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the international Dry Eye Workshop," The Ocular Surface, vol. 2007, pp. 108-152, 2007.

[104] D. C. Hood, M. Bach, M. Brigell, D. Keating, M. Kondo, J. S. Lyons, M. F. Marmor, D. L. McCulloch, A. M. Palmowski-Wolfe, "International Society For Clinical Electrophysiology of Vision. ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update)," The International Society for Clinical Electrophysiology, vol. 124 no. 1, 2021.

[105] F. Bosch-Morell, V. Villagrass, T. Ortega, N. Acero, D. Muñoz-Mingarro, M. E. González-Rosende, E. Castillo, M. A. Sanahuja, P. Soriano, I. Martínez-Soliz, "Medicinal plants and natural products as neuroprotective agents in age-related macular degeneration," Neural Regeneration Research, vol. 15 no. 12, pp. 2207-2216, DOI: 10.4103/1673-5374.284978, 2020.